Bio-Path Holdings Advances Cancer Therapies with Clinical Trial Progress and $4 Million Funding
Key Insights
Bio-Path Holdings has secured $4 million in private placement to bolster its financial position for advancing clinical trials of its cancer treatments.
Prexigebersen, Bio-Path's lead candidate, has completed Phase 1 trials for AML (search) and is in Phase 2 trials, with potential applications in obesity-related cancers (search).
BP1001-A, an enhanced version of prexigebersen, has begun Phase 1 trials for solid tumors (search), demonstrating a favorable safety profile in higher dose cohorts.
Bio-Path Holdings, Inc. (Nasdaq:BPTH) has announced significant progress in its clinical trials and secured $4 million in funding through a private placement, according to Stonegate Capital Partners. The funding aims to support the biotechnology company's operational plans in developing innovative cancer treatments.
Prexigebersen Clinical Trials
Bio-Path's lead candidate, prexigebersen, has completed Phase 1 clinical trials for acute myeloid leukemia (search) (AML (search)) and other blood cancers (search). It is currently undergoing Phase 2 trials for AML. The company is also exploring prexigebersen's potential in treating obesity (search) and obesity-related cancers (search), expanding its market reach.
Advancing Pipeline Candidates
BP1001-A, an enhanced version of prexigebersen, has entered Phase 1 trials for solid tumors (search), with the first patient treated in a higher dose cohort. The drug has demonstrated a favorable safety profile. BP1002 is in two separate Phase 1 clinical trials: one for advanced lymphoid malignancies (search) and another for refractory/relapsed AML (search) patients, including those relapsed from venetoclax-based treatment. The second dose cohort in the latter trial has been completed.
Pre-clinical Development of BP1003
BP1003 is in pre-clinical development for pancreatic cancer (search), demonstrating success in penetrating pancreatic tumors in previous trials. This highlights Bio-Path’s commitment to addressing various cancer types and stages.
DNAbilize® Technology
At the core of Bio-Path’s technology is DNAbilize®, a proprietary antisense and liposome delivery platform for DNA drugs. This approach aims to overcome challenges associated with traditional delivery methods, potentially reducing side effects. The technology's broad applicability positions Bio-Path as a potentially disruptive force in the biopharmaceutical industry.
Strategic Partnerships and Intellectual Property
Bio-Path has strategic relationships with The MD Anderson Cancer Center and other leading cancer centers, providing collaborative opportunities and access to clinical trial sites. The company's intellectual property includes composition of matter and method patents for antisense targets and manufacturing, creating barriers to entry for competitors.
Financial Position
While Bio-Path reported $0.6 million in cash on hand as of September 30, 2024, the recent $4 million private placement, closed on October 10, 2024, extends the company’s cash runway. This funding supports ongoing clinical trials and pipeline advancement.
Stonegate Capital Partners suggests that Bio-Path Holdings may be undervalued compared to its peers, considering its multiple drug candidates and approaching Phase 2 milestones for prexigebersen. Regulatory approval could significantly impact the company’s valuation.